Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Nov 1;46(11):e210-e211.
doi: 10.2337/dci23-0050.

Response to Comment on Russell et al. Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial. Diabetes Care 2023;46:1005-1013

William E Russell  1 , Daniel J Moore  2 , Kevan C Herold  3
Affiliations
Comment

Response to Comment on Russell et al. Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial. Diabetes Care 2023;46:1005-1013

William E Russell et al. Diabetes Care. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Duality of Interest. D.J.M. served on the data and safety monitoring board or advisory board for Provention Bio or received consulting fees from Provention Bio. W.E.R. received grants or contracts from Provention Bio. K.C.H. has been a consultant for Provention Bio and has received a contract from Intrexon. No other potential conflicts of interest relevant to this article were reported.

Comment on

References

    1. Pinheiro MM. Comment on Russell et al. Abatacept for delay of type 1 diabetes progression in stage 1 relatives at risk: a randomized, double-masked, controlled trial. Diabetes Care 2023;46:1005–1013 (Letter). Diabetes Care 2023;46:e209. - PubMed
    1. Feutren G, Papoz L, Assan R, et al. . Cyclosporin increases the rate and length of readmissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet 1986;2:119–123 - PubMed
    1. Silverstein J, Maclaren N, Riley W, Spillar R, Radjenovic D, Johnson S. Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N Engl J Med 1988;319:599–604 - PubMed
    1. Gitelman SE, Bundy BN, Ferrannini E, et al. .; Gleevec Trial Study Group . Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol 2021;9:502–514 - PMC - PubMed
    1. von Herrath M, Bain SC, Bode B, et al. .; Anti-IL-21–Liraglutide Study Group Investigators and Contributors . Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol 2021;9:212–224 - PubMed

MeSH terms

Grants and funding